Glioblastoma Multiforme

News Glioblastoma Multiforme

• BioInvent and ThromboGenics Announce the Start of New Study of Novel Antibody Anti-Cancer Agent TB-403 (Anti-PlGF) by Partner Roche

  BioInvent International AB  and co-development partner ThromboGenics NV announced that their partner Roche has dosed the first patient in a phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334). The trial is in patients with glioblastoma multiforme, the most common and aggressi more

• Antisense Pharma’s Trabedersen in Malignant Brain Tumors: Phase IIb Data Published in Neuro-Oncology

  Antisense Pharma announced that their international, randomized and active-controlled Phase IIb study G004-AP 12009 is published in the official journal of the American Society for Neuro-Oncology (SNO). The investigated drug trabedersen (AP 12009) is a gene silencing antisense compound – a phosphoro more

• Iron oxide nanoparticles becoming tools for brain tumor imaging and treatment

  Tiny particles of iron oxide could become tools for simultaneous tumor imaging and treatment, because of their magnetic properties and toxic effects against brain cancer cells. In mice, researchers from Emory University School of Medicine have demonstrated how these particles can deliver antibodies more

Publications Glioblastoma Multiforme

• Deciphering the 8q24.21 association for glioma

  We have previously identified tagSNPs at 8q24.21 influencing glioma risk. We have sought to fine-map the location of the functional basis of this association using data from four genome-wide association studies, comprising a total of 4147 glioma cases and 7435 controls. To improve marker density ac more

• Defining pseudoprogression in glioblastoma multiforme

  Background and purpose Pseudoprogression is a frequent phenomenon observed since the introduction of postoperative therapy with radiotherapy and temozolomide (RT/TMZ) in glioblastoma multiforme (GBM) patients. However, the criteria defining pseudoprogression, its incidence, the time of occurrenc more

• Response Classification Based on a Minimal Model of Glioblastoma Growth Is Prognostic for Clinical Outcomes and Distinguishes Progression from Pseudoprogression

  Glioblastoma multiforme is the most aggressive type of primary brain tumor. Glioblastoma growth dynamics vary widely across patients, making it difficult to accurately gauge their response to treatment. We developed a model-based metric of therapy response called Days Gained that accounts for this h more

Market studies Glioblastoma Multiforme

• Glioblastoma Multiforme (GBM) – Pipeline Review, H2 2012

  Introduction Global Markets Direct’s, 'Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Glioblastoma Multiforme (GBM), complete with latest updates, and spec more

• Glioblastoma Multiforme (GBM) – Pipeline Review, H1 2012

  Introduction Global Markets Direct’s, 'Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2012', provides an overview of the Glioblastoma Multiforme (GBM) therapeutic pipeline. This report provides information on the therapeutic development for Glioblastoma Multiforme (GBM), complete with latest u more

• Bradmer Pharmaceuticals Inc. (BMR) - Financial and Strategic SWOT Analysis Review

  Bradmer Pharmaceuticals Inc. (Bradmer) is a publicly held life sciences company that is engaged in the development and marketing of drugs for the treatment of cancer. The company focuses on the treatment of Glioblastoma multiforme (GBM), an aggressive form of brain cancer. Its lead product include N more

Websites Glioblastoma Multiforme